Sagittarius Life Science (3205.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan · ISIN TW0003205001
Sagittarius Life Science financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 467.75 m TWD | 346.08 m TWD |
| Gross profit | 81.11 m TWD | 57.71 m TWD |
| Operating income | -61.56 m TWD | -58.51 m TWD |
| EBIT | -49.47 m TWD | -49.81 m TWD |
| Net income | -48.53 m TWD | -49.56 m TWD |
| Diluted EPS – continuing operations | – | -0.73 TWD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology, as well as meat products. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
More stocks
- UJU Electronics Co. Ltd (065680.KQ)
- Halmont Properties Corporation (HMT.V)
- AnaPass Inc (123860.KQ)
- Orthex Oyj (ORTHEX.HE)
- Aluko Co Ltd (001780.KS)
- Palomino Laboratories Inc. (PALX)
- We&Win Diversification Co Ltd (4113.TWO)
- MSC Co. Ltd (009780.KQ)
- Leo Systems (5410.TWO)
- QDM International Inc. (QDMI)
- DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen (DAM.DE)
- Polaryx Therapeutics, Inc. (PLYX)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.